Cancer Calculus: An ICIJ-led collaboration with 47 media partners in 37 countries reveals how Merck & Co. keeps the price of its lifesaving cancer drug Keytruda sky-high, locking out patients and squeezing health care systems worldwide. icij.org/inves…
The yearlong investigation by 100+ journalists also sheds new light on the strategies that have allowed Merck to widen Keytruda’s use — even in cases where the benefits are limited and lower dosages may be just as effective. icij.org/inves…
Known generically as pembrolizumab, Keytruda is a game changer in cancer treatment, weaponizing a patient’s immune system against cancer cells. In the U.S., the FDA has approved it for 19 tumor types. icij.org/inves…
Keytruda’s primary patents are set to expire in 2028, but ICIJ found that Merck has continued to file and obtain secondary patents beyond the drug's main pharmaceutical component, potentially extending its commercial exclusivity until at least 2042 in the U.S. icij.org/inves…
A quiet move by the Trump administration is allowing major crypto firms to skirt U.S. state regulators that have, for years, played a key role in policing dirty money in the industry.
Critics say the shift also weakens protections for scam victims. bit.ly/4nz8b…
In 2025, the total number of direct, physical incidents of Beijing’s repression rose to 319, according to Freedom House’s latest report. But those cases just scratch the surface.
“There’s a whole universe of digital or indirect transnational repression.” buff.ly/VyjNv…
